Illinois Municipal Retirement Fund Sells 853 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Illinois Municipal Retirement Fund lowered its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 59,709 shares of the biopharmaceutical company’s stock after selling 853 shares during the period. Illinois Municipal Retirement Fund owned about 0.05% of Catalyst Pharmaceuticals worth $1,246,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Los Angeles Capital Management LLC grew its holdings in shares of Catalyst Pharmaceuticals by 1.9% in the fourth quarter. Los Angeles Capital Management LLC now owns 204,024 shares of the biopharmaceutical company’s stock worth $4,258,000 after acquiring an additional 3,742 shares during the period. Bank of New York Mellon Corp lifted its position in Catalyst Pharmaceuticals by 1.3% during the fourth quarter. Bank of New York Mellon Corp now owns 723,545 shares of the biopharmaceutical company’s stock valued at $15,100,000 after purchasing an additional 9,194 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $581,000. Navellier & Associates Inc. lifted its position in Catalyst Pharmaceuticals by 15.2% during the fourth quarter. Navellier & Associates Inc. now owns 14,163 shares of the biopharmaceutical company’s stock valued at $296,000 after purchasing an additional 1,869 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its position in Catalyst Pharmaceuticals by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company’s stock valued at $740,000 after purchasing an additional 1,000 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Up 5.7 %

NASDAQ:CPRX opened at $22.89 on Friday. The company has a market capitalization of $2.73 billion, a P/E ratio of 19.40, a P/E/G ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.47 and a 12 month high of $24.64. The business’s 50-day moving average is $22.24 and its 200 day moving average is $21.43.

Insider Buying and Selling

In related news, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares in the company, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

CPRX has been the topic of several analyst reports. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday. Stephens reiterated an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Robert W. Baird initiated coverage on Catalyst Pharmaceuticals in a research report on Tuesday, February 4th. They set an “outperform” rating and a $28.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.